Using a novel approach of integrating genome-wide, PRS, and CYP analyses, we demonstrate that higher schizophrenia-PRS and higher genotype-predicted CYP2C19 enzyme activity are independently associated with lower symptom severity while on clozapine. The gene discussed is PPIG; the disease is schizophrenia.